Global Leader of Cancer Treatments
Platform Technology of Autotelic Bio (ASODE™)
An antisense oligonucleotide (ASO) is a single-stranded deoxynucleotide that complementarily binds to the mRNA sequence of a target gene.
ASOs typically consist of 15-25 nucleotides in length and selectively bind to its target mRNA in a sequence-specific manner.
A representative inhibition mechanism is that it recognizes the RNA strand of the mRNA-oligonucleotide heteroduplex by RNAse H enzyme activity and it either removes the target mRNA through hydrolysis or binds to the translation initiation codon to block protein translation.
ASODE™ (Antisense Oligonucleotide Development)
ASODE™ (Antisense Oligonucleotide Development) is an ASO drug development platform technology that derives the optimal ASO through various evaluation stages.
ASODE™ platform technology derives the ASO sequence which is able to bind complementary to the verified target mRNA sequence and is designed through chemical modification to improve the stability and efficacy of the derived ASO sequence.
Autotelic Bio Inc. is able to develop ASO drug candidates with maximized target specificity and stability through ASODE™ technology platform.